The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis AG and Roche Holding AG as ...

Gilead Sciences (GILD) closed the most recent trading day at $121.36, moving +2.17% from the previous trading session.

Gilead Sciences (GILD) just cleared an important milestone: its once daily bictegravir and lenacapavir combo matched Biktarvy in the Phase 3 ARTISTRY 2 trial, with clean safety data that strengthens ...

Wondering if Gilead Sciences is still a smart buy after its big run, or if the stock has already priced in the good news?

Gilead Sciences (NASDAQ: GILD) has outperformed the market over the past 20 years by 2.66% on an annualized basis producing an average annual return of 11.48%. Currently, Gilead Sciences has a market ...

In this video, Jennifer A. Ligibel, MD, discusses results from the ASCENT-07 trial, in which sacituzumab govitecan did not meet its primary endpoint of PFS for patients with endocrine ...

The National blind futsal team B1, also featured in the docufilm “Lasciateci perdere”. Elena and Maria Chiara Paolini, who ...

Israeli drug discovery and development company Compugen (Nasdaq: CGEN; TASE: CGEN) today announced changes in its ...

DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, ...

The national blind futsal team, also featured in the documentary 'Lasciateci perdere'. Elettra and Maria Chiara Paolini, who ...

Combining elacestrant with targeted agents produced “clinically meaningful” outcomes for patients with locally advanced or metastatic ER-positive/HER2-negative breast cancer who have received at least ...

In a classic "flight to safety," funds have flowed into defensive market havens. Healthcare equities such as Amgen and Gilead Sciences have posted gains as investors, navigating an uncertain climate, ...